Kardium’s PULSAR Trial Results Published in JACC: A Game-Changer for Atrial Fibrillation Treatment
“Kardium’s groundbreaking PULSAR pivotal trial showcases the Globe Pulsed Field System’s superior performance in treating paroxysmal atrial fibrillation, with 95% durable pulmonary vein isolation via single applications, zero device-related primary safety events, and 78% of patients arrhythmia-free at 12 months, setting new benchmarks in procedural safety, efficiency, and patient outcomes.” The PULSAR pivotal trial stands … Read more